BIG Impact invests in autoimmune diagnostics and drug discovery startup AOI Biosciences

• BIG Impact Inc completed an investment in AOI Biosciences, a Japan-based diagnostics and drug-discovery company focused on autoimmune diseases.
• AOI Biosciences commercializes proprietary antibody testing with domestic and overseas medical institutions.
• The company is building a drug-discovery platform using quantum-related technology, targeting autoimmune disease and infectious disease programs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BIG Impact Inc published the original content used to generate this news brief on September 15, 2026, and is solely responsible for the information contained therein.